Enzo Biochem, Inc.

NYSE: ENZ
Share price (6/12/24): $1.16
Market cap (6/12/24): $59.4 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

1 Enzo Biochem, Inc. Expert Interviews, now on BamSEC.

Powered by Tegus.

Plans of Reorganization, Merger, Acquisition or Similar Filter

from 8-K 10 pages Amendment No. 1 to Asset Purchase Agreement

from 8-K 111 pages Asset Purchase Agreement Dated as of March 16, 2023 by and Among Laboratory Corporation of America Holdings, Enzo Clinical Labs, Inc. and Enzo Biochem, Inc

from DEFA14A 111 pages Asset Purchase Agreement Dated as of March 16, 2023 by and Among Laboratory Corporation of America Holdings, Enzo Clinical Labs, Inc. and Enzo Biochem, Inc

from 8-K 71 pages Asset Purchase Agreement by and Among Enzo Life Sciences, Inc., Enzo Life Sciences Acquisition, Inc., Assay Designs, Inc., Ampersand 2001 Limited Partnership and Ampersand 2001 Companion Fund Limited Partnership Dated: As of March 12, 2009

from 8-K 99 pages Stock and Asset Purchase Agreement by and Among Enzo Biochem, Inc. Enzo Life Sciences, Inc. Biomol International, Inc. Axxora (Uk) Ltd. Biomol International, L.P., Biofiniti, L.L.C., Biomol Research Laboratories, Inc., Mamhead Holding Co., LLC, Robert E. Zipkin, PH.D. Ira M. Taffer, PH.D. Paul W. Sheppard, PH.D. and Ian M. Varndell, PH.D. Dated: As of May 8, 2008 Stock and Asset Purchase Agreement

from 8-K >50 pages Plan of reorganization, merger, acquisition or similar